Form 8-K - Current report:
SEC Accession No. 0001493152-25-005563
Filing Date
2025-02-10
Accepted
2025-02-10 09:17:01
Documents
22
Period of Report
2025-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 62050
2 ex4-1.htm EX-4.1 109403
3 ex5-1.htm EX-5.1 16830
4 ex10-1.htm EX-10.1 224424
5 ex10-2.htm EX-10.2 172722
6 ex10-3.htm EX-10.3 268433
7 ex99-1.htm EX-99.1 23782
8 GRAPHIC ex5-1_001.jpg GRAPHIC 4591
9 GRAPHIC ex5-1_002.jpg GRAPHIC 1972
  Complete submission text file 0001493152-25-005563.txt   1241331

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE ocx-20250206.xsd EX-101.SCH 3012
11 XBRL LABEL FILE ocx-20250206_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE ocx-20250206_pre.xml EX-101.PRE 22358
25 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3537
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 25603915
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)